Nuvalent stock jumps as FDA review clock sharpens focus on 2026 launch plans
Nuvalent shares rose about 6% Wednesday after the company set 2026 targets for its lung cancer drug and reported $1.4 billion in cash at year-end. The FDA accepted its new drug application for zidesamtinib, with a decision expected by Sept. 18, 2026. Nuvalent plans a U.S. launch if approved and aims to file for a second lung cancer drug in early 2026.
